Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction

Diabetes Care

Volumn 41, Issue 6, 2018, Pages 1285-1291

  Rørth, Rasmus ^a,b   Jhund, Pardeep S ^a   Mogensen, Ulrik M ^a,b   Kristensen, Søren L ^a,b   Petrie, Mark C ^a   Køber, Lars ^b   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL;

ADULT; AGE; ARTICLE; ASYMPTOMATIC DISEASE; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SEX; SYSTOLIC BLOOD PRESSURE; AGED; HEART LEFT VENTRICLE FUNCTION; INCIDENCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RISK FACTOR;

AGED; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85047497547     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-2583     Document Type: Article

References (33)

1. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014;2:843-851
2. Khan SS, Butler J, Gheorghiade M. Management of comorbid diabetes mellitus and worsening heart failure. JAMA 2014;311:2379-2380
3. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108:1541-1545
4. MacDonald MR, Petrie MC, Varyani F, et al.; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377-1385
5. Held C, Gerstein HC, Yusuf S, et al.; ONTARGET/ TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007;115:1371-1375
6. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974;34:29-34
7. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res 2006;98:596-605
8. Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 2010; 55:283-293
9. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038
10. Leung AA, Eurich DT, Lamb DA, et al. Risk of heart failure in patients with recent-onset type 2 diabetes: Population-based cohort study. J Card Fail 2009;15:152-157
11. de Simone G, Devereux RB, Chinali M, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens 2010;28:353-360
12. Studies of Left Ventricular Dysfunction (SOLVD)-rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction [published correction appears in Am J Cardiol 1990;66:1026].
13. Studies of Left Ventricular Dysfunction (SOLVD)-rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 1990;66:315-322
14. Yusuf S, Pitt B, Davis CE, Hood WB Jr., Cohn JN; SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. [published correction appears in N Engl J Med 1992;327:1768].
15. Yusuf S, Pitt B, Davis CE, Hood WB Jr., Cohn JN; SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691
16. Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL. Effects of diabetes mellitus and ischemic heart disease on the progression fromasymptomatic left ventricular dysfunction to symptomatic heart failure: A retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J 2004;148:883-888
17. Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat 1978;5:141-150
18. Rogers JK, Pocock SJ, McMurray JJ, et al. Analysing recurrent hospitalizations in heart failure: A review of statistical methodology, with application to CHARM-Preserved [published correction appears in Eur J Heart Fail 2014;16:592]. Eur J Heart Fail 2014;16:33-40
19. Starling MR. Does a clinically definable diabetic cardiomyopathy exist?. J Am Coll Cardiol 1990;15:1518-1520
20. Alonso N, Moliner P, Mauricio D. Pathogenesis, clinical features and treatment of diabetic cardiomyopathy. In Advances in Experimental Medicine and Biology. Boston, MA, Springer, 2017
21. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543-567
22. MacDonald MR, Petrie MC, Home PD, et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care 2011;34: 1394-1396
23. Cooper LB, Mi X, Mentz RJ, et al. Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. Clin Cardiol 2017;40:38-45
24. Kruzliak P, Berezin A, Kremzer A, et al. Global longitudinal strain and strain rate in type two diabetes patients with chronic heart failure: Relevance to osteoprotegerin. Folia Med (Plovdiv) 2016;58:164-173
25. Debono M, Cachia E. The impact of cardiovascular autonomic neuropathy in diabetes: Is it associated with left ventricular dysfunction?. Auton Neurosci 2007;132:1-7
26. Chyun DA, Wackers FJ, Inzucchi SE, et al.; DIAD Investigators. Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. SAGE Open Med 2015;3: 2050312114568476
27. Gerstein HC, Jung H, Rydén L, Diaz R, Gilbert RE, Yusuf S; ORIGIN Investigators. Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). Circulation 2018;137:88-90
28. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: Cohort study in primary care. BMJ 2016;354:i3477
29. Varas-Lorenzo C, Margulis AV, Pladevall M, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: Systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord 2014;14:129
30. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
31. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
32. Zinman B, Wanner C, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
33. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657